CN102228059B - Disinfectant for cleaning and disinfecting dialyser - Google Patents
Disinfectant for cleaning and disinfecting dialyser Download PDFInfo
- Publication number
- CN102228059B CN102228059B CN201110220942.7A CN201110220942A CN102228059B CN 102228059 B CN102228059 B CN 102228059B CN 201110220942 A CN201110220942 A CN 201110220942A CN 102228059 B CN102228059 B CN 102228059B
- Authority
- CN
- China
- Prior art keywords
- hydrogen peroxide
- glacial acetic
- acetic acid
- quinoline
- sulfuric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004140 cleaning Methods 0.000 title claims abstract description 13
- 239000000645 desinfectant Substances 0.000 title abstract description 10
- 230000000249 desinfective effect Effects 0.000 title abstract 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 40
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 40
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 27
- 229960000583 acetic acid Drugs 0.000 claims abstract description 20
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 20
- 230000001954 sterilising effect Effects 0.000 claims description 19
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 17
- 229940033663 thimerosal Drugs 0.000 claims description 17
- 244000063299 Bacillus subtilis Species 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 241000726221 Gemma Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 239000008233 hard water Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012422 test repetition Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Abstract
The invention relates to a disinfectant for cleaning and disinfecting a dialyser. The problem of cleaning and disinfecting the dialyser can be effectively solved with cheap price. In order to solve the problem, the invention adopts the following technical scheme that: the disinfectant is prepared from the following components in percentage by weight: 85 to 90 percent of hydrogen peroxide, 8 to 10 percent of glacial acetic acid, 1 to 2 percent of sulfuric acid and 0.1 to 0.3 percent of quinoline. A preparation method of the disinfectant comprises the following steps of: adding the hydrogen peroxide into a container; sequentially adding the glacial acetic acid and the sulfuric acid with stirring; after stirring for 90 to 120 minutes at the room temperature of 18 to 25 DEG C, adding the quinoline, and stirring for 10 minutes; and standing the mixture for 3 to 4 days at the room temperature of 18 to 25 DEG C to obtain the finished product. The disinfectant is simple in the preparation method, scientific in components, low in cost, good in using effect and enormous in economic and social benefits, is easy to produce, contributes to the treatment of diseases; and the problem that the traditional disinfectant is difficult to effectively popularize and apply is effectively solved.
Description
Technical field
The present invention relates to field of medicaments, the thimerosal that particularly a kind of dialyzer cleaning and sterilizing is used.
Background technology
The dialyzer of hemodialysis, its function is exactly to play the effect of artificial kidney, the blood that human body is had to toxin, the infiltration of dialysing in suction dialyzer, getting rid of urea toxin purifies the blood, then the blood having purified is reinjected in patient body, thereby maintain patient's normal life feature, haemodialyser is in therapeutic process, urea toxin within getting rid of human body, also has the unnecessary germ of containing, as staphylococcus aureus, Escherichia coli, bacillus subtilis black variety bud cell, the harmful substances such as the precipitation of salts thing of Candida albicans are attached on dialyzer surface, so also pollute and block remarks dialyzer, therefore, the sterilization that need to clean dialyzer.Hospital needs special-purpose dialysis cleaning and sterilizing agent, but the current domestic this product that substantially do not have mostly is import Special cleaning disinfectant, and expensive, patient burden is heavy, often adds human relations (3.75L) 480-500 unit.
Nearly nearly 1,000,000 inpatient with haematological diseases of China and nephrotic, because of the high patient in hospitalize of expense approximately 100,000 about people only, the innovation of thimerosal is urgently to be resolved hurrily.
Summary of the invention
For above-mentioned situation, for overcoming prior art defect, the present invention's object is just to provide the thimerosal that a kind of dialyzer cleaning and sterilizing is used, can the effectively cheap problem that solves dialyzer cleaning and sterilizing.
The technical scheme that the present invention solves is, this cleaning agent is to be made by the component of following weight percent meter: hydrogen peroxide 85-90%, glacial acetic acid 8-10%, sulfuric acid 1-2%, quinoline 0.1-0.3%, wherein, first hydrogen peroxide is inserted in container, then in the situation that stirring, add successively glacial acetic acid, sulfuric acid, at room temperature 18-25 ℃, stir after 90-120 minute, add quinoline, then stir 10 minutes, at room temperature 18-25 ℃ standing 3-4 days (being 72-96 hour), be finished product (thimerosal of the present invention);
Described hydrogen peroxide mass concentration is 35%; The mass concentration of glacial acetic acid is 99.5%; The mass concentration of sulfuric acid is 98%.
The inventive method is simple, and prescription science is easy to produce, and cost is low, and result of use is good, has effectively overcome the problem that former thimerosal is difficult to effective popularization and application, is beneficial to the treatment of people to disease, and economic and social benefit is huge.
Embodiment
Below in conjunction with embodiment, the specific embodiment of the present invention is elaborated.
Embodiment 1
The present invention is in concrete enforcement, also can be made by the component of following weight percent meter: hydrogen peroxide 87.7%, glacial acetic acid 10%, sulfuric acid 2%, quinoline 0.3%, wherein, first hydrogen peroxide is inserted in container, then in the situation that stirring, add successively glacial acetic acid, sulfuric acid, at 18 ℃, stir after 120 minutes, add quinoline, then stir 10 minutes, at 18 ℃ of room temperatures standing 96 hours.
Embodiment 2
The present invention is in concrete enforcement, also can be made by the component of following weight percent meter: hydrogen peroxide 90%, glacial acetic acid 8%, sulfuric acid 1.8%, quinoline 0.2%, wherein, first hydrogen peroxide is inserted in container, then in the situation that stirring, add successively glacial acetic acid, sulfuric acid, at 20 ℃, stir after 100 minutes, add quinoline, then stir 10 minutes, at 20 ℃ of room temperatures standing 90 hours.
Embodiment 3
The present invention is in concrete enforcement, also can be made by the component of following weight percent meter: hydrogen peroxide 89%, glacial acetic acid 9%, sulfuric acid 1.9%, quinoline 0.1%, wherein, first hydrogen peroxide is inserted in container, then in the situation that stirring, add successively glacial acetic acid, sulfuric acid, at 25 ℃ of room temperatures, stir after 90 minutes, add quinoline, then stir 10 minutes, at 25 ℃ of room temperatures standing 72 hours.
Below in conjunction with test situation, Disinfection Effect of the present invention is specifically described:
Test A
One, material
1, experimental strain: bacillus subtilis var (CMCCC (B) 63501) brood cell.
2, disinfectant composition and content: hydrogen peroxide 288g/L, Peracetic acid 42.6g/L.
3, neutralizer composition and concentration: the PBS of 10 g/L sodium thiosulfate, 3.0% Tween-80 and 3 g/L lecithin.
4, dilution (tryptone normal saline solution), pH7.0 ± 0.2.
5, TSA medium, TSB nutrient broth.
6, constant water bath box, sterile instruments and stopwatch.
7, aseptic suction filtration system: vavuum pump, filter, 0.45 μ m miillpore filter (pall company product).
8, experiment carrier: stainless steel disk (R=12mm).
Two, method
Detect foundation: the < < of Ministry of Public Health disinfection technology standard > > 2002 editions, 2.1.2.6.4 item and 2.1.1.7.5 item.
1, neutralizer approval test: remove residual disinfectancy agent with filtration and washing method in employing, with standard hard water, dialyzer sterilization is used to concentrate by 1 ︰ 28.5(Xiao Du Ji ︰ standard hard water) dilution, be 2h action time, and test temperature is 20 ± 1 ℃, and test repeats 3 times.
2, bactericidal assay: test is with pressing 1 ︰ 28.5(Xiao Du Ji ︰ standard hard water) concentrate is used in the dialyzer sterilization of dilution, and be 5.5h, 11h and 16.5h action time, and test temperature is 20 ± 1 ℃, test repetition 3 times.
Three, result
In and filtration and washing method remove residual disinfectancy agent result of the test:
Through 3 repeated tests, prove, 1 group of growth clump count is 0cfu/ sheet, and 2 groups of growth clump counts are 75 cfu/ sheets, and 3 groups of growth clump counts are 1035000 cfu/ sheets, and 4 groups of growth clump counts are 960000 cfu/ sheets, see the following form:
Under 20 ± 1 ℃ of conditions, through 3 repeated tests, prove, with standard hard water 1 ︰ 28.5(Xiao Du Ji ︰ standard hard water) the concentrate effect 11h that uses of the dialyzer sterilization of dilution, bacillus subtilis black variety bud cell on average killed to logarithm value > 3.00, bactericidal effect reaches more than 99.99%, sees the following form:
The killing effect of thimerosal to bacillus subtilis black variety bud cell
Note: the average logarithm of positive control is planted and scope: 5.97(5.94-6.01), show that bactericidal effect is very good.
Test B:
One, material
1, experimental strain: bacillus subtilis var (CMCCC (B) 63501) brood cell.
2, disinfectant composition and content: hydrogen peroxide 288g/L, Peracetic acid 42.6g/L.
3, neutralizer composition and concentration: the PBS of 10 g/L sodium thiosulfate, 3.0% Tween-80 and 3 g/L lecithin.
4, dilution (tryptone normal saline solution), pH7.0 ± 0.2.
5, TSA medium, TSB nutrient broth.
6, constant water bath box, sterile instruments and stopwatch.
7, aseptic suction filtration system: vavuum pump, filter, 0.45 μ m miillpore filter (pall company product).
8, experiment carrier: the Medical hemostat blocking (to increment, through ungrease treatment, standby after pressuresteam sterilization by axle)
Two, method
Detect foundation: the < < of Ministry of Public Health disinfection technology standard > > 2002 editions, 2.1.2.2 item.
1, bacterial carrier preparation: carrier is fixed on aseptic supporter, gets the bacillus subtilis black variety bud cell suspension 0.02ml that contains TSB nutrient broth, drip and dye in carrier tooth portion, be coated with all, put drying for standby in 37 ℃ of insulating boxs.
2, disinfect: get aseptic plate and add with standard hard water by 1 ︰ 28.5(Xiao Du Ji ︰ standard hard water by each sample 10ml) the dialyzer sterilization of dilution is with using concentrate, put in 20 ± 1 ℃ of water-baths and be incubated after 5min, 30 samples are immersed in disinfectant solution, disinfect 11h, then with sterilizing tweezers, sample is taken out, move into respectively containing in the plastic tube of 10ml neutralizer solution.After beaing, draw 1.0ml, drip on the filter membrane of filter suction filtration.
Get an aseptic plate liquid and enter 30 ml distilled water, add 3 samples, then by experimental group sample, with method, carry out viable bacteria and cultivate counting, as positive control.
Get the neutralizer of same batch and dilution by kind of a medium, as negative control group, with batch test with together with culture medium flat plate, put in 37 ℃ of incubators and cultivate 72h, counting survival clump count, calculates and kills logarithm and plant.
Three, result
Under 20 ± 1 ℃ of water bath condition, with standard hard water by 1 ︰ 28.5(Xiao Du Ji ︰ standard hard water) the dialyzer sterilization of dilution used concentrate effect 11h, bacillus subtilis black variety bud cell on 30 medicine equipment carrier samples is on average killed to logarithm and plant > 5.00, bactericidal effect reaches more than 99.9999%.
The present invention has also done the test of above-mentioned same method to staphylococcus aureus, Escherichia coli and Candida albicans, sterilization has all been obtained to extraordinary effect, and concrete condition is explained no longer one by one.
Thimerosal of the present invention is through the actual use to dialyzer, during use, it is 3.5% thimerosal that thimerosal thin up is become to mass concentration, after more than 10 hours immersion to dialyzer, after tested, Disinfection Effect is very good, and to all reaching 3.0-5.0 as the logarithm value of killing of staphylococcus aureus, Escherichia coli, bacillus subtilis black variety bud cell, Candida albicans, sterilizing rate is up to 99.99-99.9999%; To thimerosal composition test, final products, wherein effective mass composition content of hydrogen peroxide is 24.3-29.7%, the best is 27%; Peracetic acid content is 4.5-5.5%, is preferably 5.0%; PH value 0.1-0.5.
In a word, cost of the present invention is low, easily produces, and sterilization effect is good, is effective to the dialysis treatment of hematologic disease and ephrosis, greatly alleviates patient's financial burden, makes and benefits society, and economic and social benefit is huge.
Claims (4)
1. the thimerosal that dialyzer cleaning and sterilizing is used, it is characterized in that, component by following weight percent meter is made: hydrogen peroxide 87.7-90%, glacial acetic acid 8-10%, sulfuric acid 1-2%, quinoline 0.1-0.3%, wherein, first insert hydrogen peroxide in container, again in the situation that stirring, add successively glacial acetic acid, sulfuric acid, stir after 90-120 minute at room temperature 18-25 ℃, add quinoline, stir again standing 3-4 days at room temperature 18-25 ℃ 10 minutes;
Described hydrogen peroxide mass concentration is 35%; The mass concentration of glacial acetic acid is 99.5%; The mass concentration of sulfuric acid is 98%; Described thimerosal is bacillus subtilis black variety gemma, staphylococcus aureus, Escherichia coli and Candida albicans to be possessed to the thimerosal of bactericidal effect.
2. the thimerosal that dialyzer cleaning and sterilizing according to claim 1 is used, it is characterized in that, component by following weight percent meter is made: hydrogen peroxide 87.7%, glacial acetic acid 10%, sulfuric acid 2%, quinoline 0.3%, wherein, first hydrogen peroxide is inserted in container, again in the situation that stirring, add successively glacial acetic acid, sulfuric acid, stir after 120 minutes at 18 ℃, add quinoline, stir again at 18 ℃ of room temperatures standing 96 hours 10 minutes.
3. the thimerosal that dialyzer cleaning and sterilizing according to claim 1 is used, it is characterized in that, component by following weight percent meter is made: hydrogen peroxide 90%, glacial acetic acid 8%, sulfuric acid 1.8%, quinoline 0.2%, wherein, first hydrogen peroxide is inserted in container, again in the situation that stirring, add successively glacial acetic acid, sulfuric acid, stir after 100 minutes at 20 ℃, add quinoline, stir again at 20 ℃ of room temperatures standing 90 hours 10 minutes.
4. the thimerosal that dialyzer cleaning and sterilizing according to claim 1 is used, it is characterized in that, component by following weight percent meter is made: hydrogen peroxide 89%, glacial acetic acid 9%, sulfuric acid 1.9%, quinoline 0.1%, wherein, first hydrogen peroxide is inserted in container, again in the situation that stirring, add successively glacial acetic acid, sulfuric acid, at 25 ℃ of room temperatures, stir after 90 minutes, add quinoline, stir again at 25 ℃ of room temperatures standing 72 hours 10 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110220942.7A CN102228059B (en) | 2011-08-03 | 2011-08-03 | Disinfectant for cleaning and disinfecting dialyser |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110220942.7A CN102228059B (en) | 2011-08-03 | 2011-08-03 | Disinfectant for cleaning and disinfecting dialyser |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102228059A CN102228059A (en) | 2011-11-02 |
| CN102228059B true CN102228059B (en) | 2014-03-19 |
Family
ID=44840695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110220942.7A Active CN102228059B (en) | 2011-08-03 | 2011-08-03 | Disinfectant for cleaning and disinfecting dialyser |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102228059B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081568A (en) * | 1992-07-29 | 1994-02-09 | 苏汝好 | The compound method of sweet smell disinfectant |
| CN1823710A (en) * | 2004-12-03 | 2006-08-30 | 莱雅公司 | Composition for bleaching and simultaneously dyeing keratin fibers, comprising quinoline or a quinoline derivative |
| CN101785746A (en) * | 2008-12-12 | 2010-07-28 | 莱雅公司 | Use the colouring method that comprises wiping, drying or non-rinse step of neighbour-Benzodiazepines |
-
2011
- 2011-08-03 CN CN201110220942.7A patent/CN102228059B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081568A (en) * | 1992-07-29 | 1994-02-09 | 苏汝好 | The compound method of sweet smell disinfectant |
| CN1823710A (en) * | 2004-12-03 | 2006-08-30 | 莱雅公司 | Composition for bleaching and simultaneously dyeing keratin fibers, comprising quinoline or a quinoline derivative |
| CN101785746A (en) * | 2008-12-12 | 2010-07-28 | 莱雅公司 | Use the colouring method that comprises wiping, drying or non-rinse step of neighbour-Benzodiazepines |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102228059A (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1816330B (en) | Antiseptic compositions, methods and systems | |
| US10617715B2 (en) | Methods of treating or preventing biofilm associated infections with free available chlorine free available chlorine water | |
| CN102389743A (en) | Formula of medical bacteriostatic humidifying solution | |
| CN112841222A (en) | Antibacterial and antivirus material and application thereof | |
| CN102349548A (en) | Environment biological disinfectant with phages as main components and application thereof | |
| CN102228059B (en) | Disinfectant for cleaning and disinfecting dialyser | |
| CN102784100B (en) | Medical biocolloid solution for sterilization and preparation method thereof | |
| CN105543820B (en) | A kind of preparation method of stainless steel medical apparatus surface anti-bacterial attachment coating | |
| Hong et al. | The Application of Silver to Decontaminate Dental Unit Waterlines—A Systematic Review | |
| CN110278964A (en) | Lactobacillus plantarum ACCC11016 is inhibiting the application in aspergillus flavus | |
| Wangchuk et al. | Antimicrobial property of hydrocolloid impression material incorporated with silver nanoparticles against staphylococcus aureus | |
| CN105296362A (en) | Aspergillus fumigatus biofilm flow model | |
| CN109612988A (en) | A method of test confined space ozone disinfection effect | |
| TW202108187A (en) | Methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby | |
| Jawad et al. | Disinfection of Drinking Water from Escherichia coli and Pseudomonas aeruginosa by Using Silver Nanoparticles | |
| CN107789372A (en) | A kind of preparation method of microbial metabolism organic acid antibacterial liquid | |
| CN102552650A (en) | Skin antibacterial agent and preparation method thereof | |
| CN112471174B (en) | Nano-silver/domiphen bromide composite antibacterial agent and preparation method and application thereof | |
| CN108654531A (en) | A kind of synthesis of artificial cell membrane nano silver coating reaction kettle | |
| RU2709720C1 (en) | Method of treating staphylococcus aureus culture with oxygen-containing gas from portable ozoniser | |
| JP3680125B2 (en) | Anti-inflammatory method and anti-inflammatory solution for ungulate mastitis | |
| CN107593763A (en) | A kind of thimerosal of haemodialysis control unit and preparation method thereof | |
| CN104430621A (en) | Agent for sterilizing intensive care unit | |
| CN115152793A (en) | Purifying agent for ICU ward purification and preparation method thereof | |
| Jensen et al. | Evaluation of a germicidal device for peritoneal dialysis connectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LUOYANG YUANYANG BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER OWNER: LUOYANG YUANYANG MEDICAL APPARATUS CO.,LTD. Effective date: 20140520 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140520 Address after: 471941, Luoyang Town, Henan City, Yanshi Province Industrial Zone Patentee after: Luoyang Yuanyang Biological Pharmaceutical Co.,Ltd. Address before: 471941, Luoyang Town, Henan City, Yanshi Province Industrial Zone Patentee before: Luoyang Yuanyang Medical Apparatus Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Disinfectant for cleaning and disinfecting dialyser Effective date of registration: 20190603 Granted publication date: 20140319 Pledgee: Bank of China, Limited by Share Ltd, Luoyang branch Pledgor: Luoyang Yuanyang Pharmaceutical Co., Ltd. Registration number: 2019990000508 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200629 Granted publication date: 20140319 Pledgee: Bank of China Limited by Share Ltd. Luoyang branch Pledgor: LUOYANG OCEAN BIOPHARMACEUTICAL Co.,Ltd. Registration number: 2019990000508 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |